Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Summary

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

Eligibility

Inclusion Criteria:

1. Adults aged 18 years and older at the time of informed consent;
2. Diagnosis of rheumatic disease: rheumatoid arthritis (RA), psoriatic arthritis (PA) , ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), spondyloarthritis, polymyalgia rheumatica, giant cell arteritis, vasculitis, granulomatosis with polyangiitis, dermatomyositis, polymyositis, and inflammatory bowel disease-associated arthritis;
3. On active immunosuppression for at least 3 months prior to scheduled surgery;
4. Scheduled for elective total shoulder arthroplasty;
5. Able and willing to provide written informed consent prior to any study specific procedures.

Exclusion Criteria:

* Patients with active infections or malignancies;
* Patients undergoing shoulder arthroplasty for fracture or tumor;
* Pregnancy or breastfeeding;
* Unable to provide informed consent;
* Patients with severe SLE with marked activity - as they should be offered enrollment in the observational arm. All such patients should remain on treatment to avoid worsening of disease activity;
* Unable or without capacity to provide written informed consent prior to any study specific procedures.

Conditions3

Interventions27

Locations1 site

Find trials near these locations

Related trials

• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies — Federal Research Institute of Pediatric Hematology, Oncology and Immunology
• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis — Duke University
• Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response — University of Nebraska
• HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT — Duke University
• ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — Leland Metheny
• Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis — Tom Appleton
• Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA) — Universita di Verona
• Swiss Dermatology Network of Targeted Therapies (SDNTT) — Swiss Dermatology Network for Targeted Therapies

Browse More Trials